Genetesis
Genetesis: A fast-growing medical imaging firm using data science and biomagnetism to combat heart disease.
Founded
2013Genetesis: A fast-growing medical imaging firm using data science and biomagnetism to combat heart disease.
Founded in 2013, Genetesis is a medical imaging company dedicated to revolutionizing cardiovascular disease diagnosis through advanced data science and biomagnetism. The company's core mission is to provide rapid, non-invasive, and radiation-free diagnostic solutions for detecting myocardial ischemia. Their flagship product, CardioFlux, utilizes magnetocardiography (MCG) to identify functionally significant ischemia at its earliest stages, offering a safer and more efficient alternative to traditional stress testing methods.
Notable affiliates of Genetesis include leading cardiologists and biomedical engineers who contribute to the company's innovative approach. The company has attracted significant investment from venture capital firms focused on healthcare technology. Key achievements include FDA clearance for their CardioFlux system and successful clinical trials demonstrating its efficacy. Genetesis has made a substantial impact on the medical community by providing a faster, safer diagnostic tool, potentially improving outcomes for patients with cardiovascular disease.
Companies similar to Genetesis include HeartVista, Myocardial Solutions, MagBiosense and Dyad Medical.
Genetesis was founded in 2013.
Genetesis' headquarters is located in Mason, OH, US.
Genetesis' most recent funding round was for $17.5M (USD) in October 2022.
As of Oct 6, 2022, Genetesis has disclosed funding of $35.8M (USD). Undisclosed round amounts are excluded.
Genetesis has 37 employees as of Feb 5, 2024.
dyadmed.com
